Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis

Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study

(2022) Alessandro Rizzo et al.   Expert Opinion on Drug Metabolism & Toxicology

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial

(2021) Paul Baas et al.   LANCET

Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331☆

(2021) D.R. Spigel et al.   ANNALS OF ONCOLOGY

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

(2021) Ahmet Sezer et al.   LANCET

Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial

(2021) Eric P Winer et al.   LANCET ONCOLOGY

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

(2021) Toni K. Choueiri et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

(2021) Robert Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pemetrexed Plus Platinum With or Without Pembrolizumab in Patients With Previously Untreated Metastatic Nonsquamous NSCLC: Protocol-Specified Final Analysis From KEYNOTE-189

(2021) D. Rodríguez-Abreu et al.   ANNALS OF ONCOLOGY

Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

(2021) Nancy Y Lee et al.   LANCET ONCOLOGY

Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer

(2021) S. Sugawara et al.   ANNALS OF ONCOLOGY

Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials

(2021) Francesco Massari et al.   EUROPEAN JOURNAL OF CANCER

Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma

(2021) Huiyan Luo et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA)

(2021) Junzo Hamanishi et al.   JOURNAL OF CLINICAL ONCOLOGY

Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial

(2021) Shun Lu et al.   Journal of Thoracic Oncology

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study

(2021) Jong-Mu Sun et al.   LANCET

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

(2021) Yelena Y Janjigian et al.   LANCET

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

(2021) Thomas Powles et al.   LANCET ONCOLOGY

Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study

(2021) Eric Pujade-Lauraine et al.   LANCET ONCOLOGY

Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial

(2021) Bradley J Monk et al.   LANCET ONCOLOGY

Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial

(2021) Yunpeng Yang et al.   LANCET ONCOLOGY

Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

(2021) Nicoletta Colombo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma

(2021) Veronica Mollica et al.   Targeted Oncology

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update

(2021) M. Reck et al.   ESMO Open

Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma

(2020) Ann-Lii Cheng et al.   JOURNAL OF HEPATOLOGY

Pembrolizumab for Early Triple-Negative Breast Cancer

(2020) Peter Schmid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Health-related quality of life in cancer patients treated with immune checkpoint inhibitors: A systematic review on reporting of methods in randomized controlled trials

(2020) Stéphane Faury et al.   PLoS One

Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma

(2020) T.K. Choueiri et al.   ANNALS OF ONCOLOGY

Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-mesothelin (CRS-207) With or Without Nivolumab in Patients with Pancreatic Cancer

(2020) Takahiro Tsujikawa et al.   CLINICAL CANCER RESEARCH

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study

(2020) Charles M. Rudin et al.   JOURNAL OF CLINICAL ONCOLOGY

Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial

(2020) Matthew D Galsky et al.   LANCET

Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study

(2020) Jing Huang et al.   LANCET ONCOLOGY

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

(2020) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma

(2020) David A. Reardon et al.   JAMA Oncology

Clinical Challenges of Immune Checkpoint Inhibitors

(2020) Maria de Miguel et al.   CANCER CELL

A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous Non–Small-Cell Lung Cancer: Protocol-Specified Final Analysis of KEYNOTE-407

(2020) Luis Paz-Ares et al.   Journal of Thoracic Oncology

Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

(2020) Ralf Gutzmer et al.   LANCET

Sequencing Therapies for Metastatic Renal Cell Carcinoma

(2020) Nazli Dizman et al.   UROLOGIC CLINICS OF NORTH AMERICA

A decade of immune-checkpoint inhibitors in cancer therapy

(2020) Caroline Robert   Nature Communications

Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: a systematic review and meta-analysis

(2020) Francesco Massari et al.   Expert Opinion On Drug Safety

Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC

(2020) Mark M. Awad et al.   Journal of Thoracic Oncology

Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial

(2020) Elizabeth A Mittendorf et al.   LANCET

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

(2020) Thomas Powles et al.   LANCET ONCOLOGY

Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial

(2020) Thomas Powles et al.   LANCET ONCOLOGY

Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma

(2020) Thomas Powles et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer

(2020) Sara M. Tolaney et al.   JAMA Oncology

Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer

(2020) Kohei Shitara et al.   JAMA Oncology

Improving safety of cancer immunotherapy via delivery technology

(2020) Doudou Hu et al.   BIOMATERIALS

Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100

(2020) Markus Moehler et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer

(2020) Thierry André et al.   NEW ENGLAND JOURNAL OF MEDICINE

Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial

(2020) Caicun Zhou et al.   Lancet Respiratory Medicine

KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma

(2020) Pier Francesco Ferrucci et al.   Journal for ImmunoTherapy of Cancer

Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non–Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel

(2019) Zhijie Wang et al.   JAMA Oncology

Complete response associated with immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis of nine randomized controlled trials

(2019) Jie Li et al.   Cancer Management and Research

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

(2019) Brian I. Rini et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial

(2019) Yi-Long Wu et al.   Journal of Thoracic Oncology

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

(2019) Y Fradet et al.   ANNALS OF ONCOLOGY

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

(2019) Tony S K Mok et al.   LANCET

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

(2019) Brian I Rini et al.   LANCET

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

(2019) Howard West et al.   LANCET ONCOLOGY

Immunotherapy for renal cell carcinoma

(2019) Iris Y. Sheng et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial

(2019) Cathy Eng et al.   LANCET ONCOLOGY

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial

(2019) Ken Kato et al.   LANCET ONCOLOGY

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

(2019) Matthew D. Hellmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial

(2019) Hiroyuki Nishiyama et al.   International Journal of Clinical Oncology

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

(2019) Luis Paz-Ares et al.   LANCET

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

(2019) Barbara Burtness et al.   LANCET

The evolving role of PD-L1 testing in patients with metastatic urothelial carcinoma

(2019) Thomas Powles et al.   CANCER TREATMENT REVIEWS

Cabozantinib in Combination with Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence

(2019) Paulo Bergerot et al.   MOLECULAR CANCER THERAPEUTICS

Cancer Immunotherapy: Factors Important for the Evaluation of Safety in Nonclinical Studies

(2018) Danuta J. Herzyk et al.   AAPS Journal

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

(2018) Thomas Powles et al.   LANCET

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

(2018) Mark A. Socinski et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

(2018) Leena Gandhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

(2018) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

CheckMate 141: 1‐Year Update and Subgroup Analysis of Nivolumab as First‐Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer

(2018) Maura L. Gillison et al.   ONCOLOGIST

Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300

(2018) Y -J Bang et al.   ANNALS OF ONCOLOGY

Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma

(2018) Xin Gao et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study

(2018) Fabrice Barlesi et al.   LANCET ONCOLOGY

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

(2018) Leora Horn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

(2018) Luis Paz-Ares et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

(2018) Ezra E W Cohen et al.   LANCET

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

(2018) Peter Schmid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non–Small-Cell Lung Cancer

(2017) Ramaswamy Govindan et al.   JOURNAL OF CLINICAL ONCOLOGY

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

(2017) Achim Rittmeyer et al.   LANCET

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

(2017) Aaron M. Goodman et al.   MOLECULAR CANCER THERAPEUTICS

First FDA Approval Agnostic of Cancer Site — When a Biomarker Defines the Indication

(2017) Steven Lemery et al.   NEW ENGLAND JOURNAL OF MEDICINE

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

(2017) Zachary R. Chalmers et al.   Genome Medicine

RECIST 1.1—Update and clarification: From the RECIST committee

(2016) Lawrence H. Schwartz et al.   EUROPEAN JOURNAL OF CANCER

Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer

(2016) Martin Reck et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?

(2015) L. Apetoh et al.   ANNALS OF ONCOLOGY

Cancer immunotherapy: harnessing the immune system to battle cancer

(2015) Yiping Yang   JOURNAL OF CLINICAL INVESTIGATION

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

(2015) Antoni Ribas et al.   LANCET ONCOLOGY

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

(2015) Jeffrey S Weber et al.   LANCET ONCOLOGY

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma

(2013) Antoni Ribas et al.   JOURNAL OF CLINICAL ONCOLOGY

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement

(2010) David Moher et al.   International Journal of Surgery